Homology Medicines, Inc. (FIXX): Price and Financial Metrics


Homology Medicines, Inc. (FIXX)

Today's Latest Price: $15.34 USD

0.09 (0.59%)

Updated Jul 2 4:00pm

Add FIXX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FIXX Stock Summary

  • FIXX's went public 2.26 years ago, making it older than merely 6.17% of listed US stocks we're tracking.
  • FIXX's price/sales ratio is 346.16; that's higher than the P/S ratio of 98.81% of US stocks.
  • As for revenue growth, note that FIXX's revenue has grown -36.63% over the past 12 months; that beats the revenue growth of only 5.39% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Homology Medicines Inc, a group of peers worth examining would be PTGX, SNDX, ATHX, QURE, and OTIC.
  • Visit FIXX's SEC page to see the company's official filings. To visit the company's web site, go to www.homologymedicines.com.
FIXX Daily Price Range
FIXX 52-Week Price Range

FIXX Stock Price Chart Technical Analysis Charts


FIXX Price/Volume Stats

Current price $15.34 52-week high $24.00
Prev. close $15.25 52-week low $11.05
Day low $15.10 Volume 246,127
Day high $15.50 Avg. volume 356,845
50-day MA $14.55 Dividend yield N/A
200-day MA $16.06 Market Cap 693.57M

Homology Medicines, Inc. (FIXX) Company Bio


Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.


FIXX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

FIXX Latest Social Stream


Loading social stream, please wait...

View Full FIXX Social Stream

Latest FIXX News From Around the Web

Below are the latest news stories about Homology Medicines Inc that investors may wish to consider to help them evaluate FIXX as an investment opportunity.

Four biotech names heading for key Q3 catalysts

Four names in biotechnology are seeing call-outs from Baird for potentially significant upside, and third-quarter catalysts that could give their stocks a boost. Two of the stocks get Fresh Pick status in a note from analyst Madhu Kumar. Homology Medicines (FIXX) is seeing an impressive risk/reward profile, the firm says,...

Seeking Alpha | July 2, 2020

Biogen and Southwest Are on the Casualty List

In a climate of rampant uncertainty, what should an investor do? Continue reading...

Yahoo | June 29, 2020

Homology Medicines, Inc. (FIXX): Hedge Funds Are Snapping Up

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 27, 2020

7 Biotech Stocks Wall Street Says Will Double or More

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and fl...

Yahoo | May 19, 2020

Homology Medicines, Inc. (NASDAQ:FIXX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

The quarterly results for Homology Medicines, Inc. (NASDAQ:FIXX) were released last week, making it a good time to...

Yahoo | May 10, 2020

Read More 'FIXX' Stories Here

FIXX Price Returns

1-mo -2.91%
3-mo -7.81%
6-mo -16.68%
1-year -15.81%
3-year N/A
5-year N/A
YTD -25.89%
2019 -7.42%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching FIXX

Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:

Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0078 seconds.